Financial statements Syntalpharma
Balance sheet data of SYNTALPHARMA
Year
|
2021
|
2022
|
2023
|
---|---|---|---|
Total assets | 1 618 549,92 | 2 150 351,70 | 2 577 340,97 |
A. Fixed assets | 732 292,10 | 672 966,50 | 943 553,01 |
B. Current assets | 886 257,82 | 1 477 385,20 | 1 633 787,96 |
C. Share capital contributions (basic funds) | 0,00 | 0,00 | 0,00 |
D. Own shares (stocks) | 0,00 | 0,00 | 0,00 |
Total liabilities | 1 618 549,92 | 2 150 351,70 | 2 577 340,97 |
A. Equity | 72 571,98 | 630 736,19 | 1 112 047,09 |
B. Liabilities and provisions for liabilities | 1 545 977,94 | 1 519 615,51 | 1 465 293,88 |
I. Long-term liabilities | 1 341 189,82 | 1 436 410,42 | 1 458 325,86 |
II. Short-term liabilities | 204 788,12 | 83 205,09 | 6 968,02 |
Financial data is automatically retrieved from the EKRS webpage of the Ministry of Justice.
- Fixed Assets - Assets held for a longer period, typically longer than a year, such as real estate or machinery.
- Current Assets - Assets intended to be used or sold within a year, such as inventory, receivables, and cash.
- Equity - The net value of a company's assets, representing the difference between its assets and liabilities.
- Long-Term Liabilities - Financial obligations to be repaid over a period longer than a year, such as loans or bonds.
- Short-Term Liabilities - Financial obligations to be repaid within a year, such as payables to suppliers or short-term loans.
- Reserve Capital - A portion of equity set aside for specific purposes, such as covering losses or business development.